

EPIC DIABETES CONFERENCE

MAY 22, 2021 | 8:30 AM - 2:45 PM

EMPOWERING PATIENTS
FOR
INDIVIDUALIZED CARE



HOSTED BY:

Barbara Davis Center for Diabetes

and the

Children's Diabetes Foundation

#EPIConf2021

www.EPIConferences.org



THANK YOU TO TODAY'S
PRESENTING SPONSOR



BEATSON
FOUNDATION

#EPIConf2021

www.EPIConferences.org



CONFERENCE SCHEDULE

8:30-9:00 AM Welcome and Diabetes Today (All Tracks) – Sarit Polsky, MD, MPH

9:00-10:00 AM Connections between Diabetes and Bodily Health

Adult Track

Remote Monitoring:

Digital Diabetes Communication

Aaron Michels, MD

Pediatric Track

Remote Monitoring:

Rules of Engagement

Holly O'Donnell, PhD

Advanced Track

Diabetes Affects Others:

Supporters & Caregivers

Jane Reusch, MD and

Brigitte Frohnert, MD, PhD

10:00-11:00 AM Connections between Diabetes and Mental/Emotional Health

Adult Track

Adult Mental/Emotional Health

Viral Shah, MD and

Jenna Eisenberg, MS, LMFT

Pediatric Track

Pediatric Mental/Emotional Health

Shideh Majidi, MD and

Ellen Fay-Itzkowitz, MS

Advanced Track

Online Decision Support

Robert Slover, MD



#EPIConf2021

www.EPIConferences.org



CONFERENCE SCHEDULE

11:00 AM – 12:00 PM Covid-19 and Diabetes (All Tracks) – Todd Alonso, MD

12:00 – 12:30 PM Lunch Break

12:30-1:30 PM Session 3

Adult Track

Diabetes Advise and Resources
Cecilia Low Wang, MD

Pediatric Track

*Community Connections for
Children and Adolescents*
Kimber Simmons, MD

Advanced Track

*Diabetes' Connection to Other
Health Disorders*
Alexandra Reiher, MD and
Taylor Triolo, MD



#EPIConf2021

www.EPIConferences.org



CONFERENCE SCHEDULE

1:30 – 2:15 PM Moderator: Sarit Polsky, MD, MPH

Keynote Address

Connectivity

Kellee Miller, PhD (Senior Epidemiologist at the Jaeb Center for Health Research and for the T1D Exchange Clinic Network and Registry)

2:15-2:30 PM Keynote Q&A

2:30-2:45 PM Closing Remarks – Greg Forlenza, MD



#EPIConf2021

www.EPIConferences.org



HAVE QUESTIONS DURING A PRESENTATION?

List your comments or questions in the “Chat” feature at the bottom of the screen.

Your comments/questions will be addressed by the moderator at the end of each presentation.

**Need IT help or support?
Call Paul at (720) 219-0475**



#EPIConf2021

www.EPIConferences.org



THANK YOU TO OUR
SUPPORTING SPONSOR

Dexcom

#EPICconf2021

www.Dexcom.com





Barbara Davis
Center for Diabetes

UNIVERSITY OF COLORADO
ANSCHUTZ MEDICAL CAMPUS

www.BarbaraDavisCenter.org

303-724-2323

#EPIConf2021

www.EPICconferences.org





DONATIONS APPRECIATED!

Please consider making a donation to:

Children's Diabetes Foundation
to support this conference for future years.



ChildrensDiabetesFoundation.org/Donate

#EPIConf2021

www.EPIConferences.org



Informational and product handouts from our sponsors are available to all participants.

The next few slides will include contact information for some diabetes companies and a QR code that you scan with your phone camera to direct you to a sponsor's handouts.

We invite you to reach out to these reps with any questions or interest!

SCAN ME!



All Sponsor Handouts

dexcom

omnipod[®]
simplify life™



TANDEM[®]
DIABETES CARE

Lilly

Dexcom

Contact: Ellen Elliott

Phone: (303) 520-8579

Email: eelliott@dexcom.com



#EPIConf2021

www.Dexcom.com



Dexcom Handouts

All Sponsor Handouts



Contact: Dino Pierce, RDN, CDCES

Phone: (985) 860-0000

Email: dpierce@insulet.com



All Sponsor Handouts

#EPIConf2021

www.OmniPod.com



OmniPod Handouts



TANDEM®
DIABETES CARE

Contact: Angie Walker

Phone: (303) 570-2906



Email: AWalker@tandemdiabetes.com



#EPIConf2021

www.TandemDiabetes.com



All Sponsor Handouts

Tandem Handouts



Learn more at www.Lilly.com

Consumer questions- 1.800.LillyRX

Lilly is the sole owner of all right, title, and interest to all Lilly information, including Lilly logos, trademarks, name, trade names, and copyrighted materials ("Lilly Property"). When the sponsorship or partnership is terminated or expires, the sponsor/partner should discontinue the use of all Lilly Property.



#EPIConf2021

www.Lilly.com



Lilly.com

All Sponsor Handouts

THANK YOU TO TODAY'S
PRESENTING SPONSOR



BEATSON
FOUNDATION

#EPIConf2021

www.EPIConferences.org



BARBARA DAVIS CENTER RESEARCH STUDIES

The following slides will contain information on current and upcoming Barbara Davis Center research studies.

If you are interested in participating in a study, please reach out to the contact for that project (information located on the slide)



#EPIConf2021

www.EPIConfferences.org



BONE HEALTH IN ADULTS WITH TYPE 1 DIABETES

Inclusion: Men over 50 years and women over 45 years

Exclusion: Intake of osteoporosis medications, history of cancer with chemo or radiation therapy, parathyroid disease, rheumatologic disease, use of immunosuppressant or steroid medications.

Study includes 4-5 visits over the course of 4 years.

Contact Information

Prakriti Joshee
303-724-9925

Prakriti.joshee@cuanschutz.edu



#EPIConf2021

Prakriti.joshee@cuanschutz.edu



AUTOIMMUNITY SCREENING FOR KIDS (ASK) STUDY

Autoimmunity Screening for Kids (ASK) study. ASK is a free screening for type 1 diabetes and celiac disease risk for all Colorado children ages 1-17 and their parents. The ASK study also offers an optional SARS-CoV-2 antibody screen.

For more information and to complete the electronic consent, please visit the ASK website at www.ASKhealth.org or call 303-724-1275 for more information.



#EPIConf2021

www.ASKhealth.org



THE PROTECT STUDY

Children and adolescents with newly-diagnosed type 1 diabetes will receive two 12-day courses of teplizumab IV infusions. Teplizumab appears to interfere with the cells that destroy the insulin-producing beta cells in the pancreas.

Individuals with T1D receiving teplizumab may be able to continue making more of their own insulin, which may reduce the need for insulin injections and allow for better glucose control and/or fewer complications of T1D.

2 out of 3 chance to receive teplizumab vs placebo

Participants will be compensated

Who can participate?

Ages 8-17 years old

Recent diagnosis of T1D (ideal to enroll by 3 weeks after diagnosis as teplizumab infusions must start within 6 weeks of diagnosis)

Contact Information

Lexie Chesshir

303-724-1755

LEXIE.CHESSHIR@CUANSCHUTZ.EDU



#EPIConf2021

LEXIE.CHESSHIR@CUANSCHUTZ.EDU



BARBARA DAVIS CENTER COLORADO CGM PROGRAM

21 years or older, on Medicaid or uninsured
and cannot obtain a CGM due to insurance.

Contact Information
Katie Thivener
Office 303-724-9998

katelin.thivener@cuanschutz.edu



#EPIConf2021

katelin.thivener@cuanschutz.edu



USE OF THE GUARDIAN™ CONNECT SYSTEM WITH SMART CONNECTED DEVICES

3-month participation for patients with T1D 2-17 years of age on MDI therapy. Involves the use of a smart InPen, the Medtronic Guardian Connect system, as well as food logging. Participants will use a study provided smart phone, apple watch (>14yo), InPen and Guardian system for study duration. Participation is paid.

Contact Information

Emily Fivekiller

Office 303-724-8916

Cell 720-446-8078

Emily.Fivekiller@CUAnschutz.edu



#EPIConf2021

Emily.Fivekiller@CUAnschutz.edu



DAILY PREDICTORS OF DIABETES SELF-MANAGEMENT IN ADOLESCENTS/YOUNG ADULTS WITH DIABETES

2-week participation for patients with T1D 14-26 years of age currently using pump/smart pen and CGM therapy. Involves the completion of surveys on 8 different days in the morning and evening. All surveys are sent via a text message to the participants and should take no more than 5 minutes to complete.

Participation is paid.

Contact Information

Emily Fivekiller

Office 303-724-8916

Cell 720-446-8078

Emily.Fivekiller@CUAnschutz.edu



#EPIConf2021

Emily.Fivekiller@CUAnschutz.edu



THE PEDIATRIC ARTIFICIAL PANCREAS (PEDAP) TRIAL: A RANDOMIZED CONTROLLED COMPARISON OF THE CONTROL-IQ TECHNOLOGY VERSUS STANDARD CARE IN YOUNG CHILDREN IN TYPE 1 DIABETES

The main purpose of this study is to look at how well an investigational automated insulin delivery system (Tandem Control-IQ) works in young children (2-<6 years old) who are diagnosed with Type 1 Diabetes (for at least 6 months). This is a randomized control trial that is looking to compare the Tandem t:slim X2 Control-IQ pump to a standard insulin pump or daily injections.

Contact Information
Cari Berget
Office 720-454-6938
cari.berget@cuanschutz.edu

#EPIConf2021
cari.berget@cuanschutz.edu



“FOCUS”

Criteria

Over 18 years old

Have type 2 diabetes

Mild to Moderate Retinopathy

Contact Information

Drake Giese

Office (303)-724-3878

Drake.Giese@cuanschutz.edu



#EPIConf2021

Drake.Giese@cuanschutz.edu



(PICLS) PREGNANCY INTERVENTION WITH A CLOSED LOOP SYSTEM!

Do you have Type 1 Diabetes?

Are you interested in the world's first hybrid closed-loop system?

We are looking for pregnant women with T1D to participate in the PICLS study.

We are looking for women with T1D that are less than 9 weeks into pregnancy.

This is a pilot study evaluating hybrid closed-loop (HCL) insulin delivery compared with sensor-augmented pump therapy (SAPT) throughout pregnancy and the first 6 weeks after delivery.

Are there benefits for study volunteers?

Participants are provided an advanced insulin pump and continuous glucose monitoring technologies

Financial compensation is also offered for completing study visits

If you are interested in participating in the PICLS Study, please contact:

Dr. Sarit Polksky, principal investigator: Sarit.Polsky@cuanschutz.edu, 303-724-8575 or

Lisa Sher, research coordinator: Lisa.Sher@cuanschutz.edu, 303-724-8369



#EPIConf2021

Sarit.Polsky@cuanschutz.edu



TRIALNET PATHWAY TO PREVENTION (TN01)

A free blood test to detect your risk of T1D years before symptoms appear.

Participants receive close monitoring—their risk of being diagnosed in diabetic ketoacidosis (DKA) decreases from 30% to less than 4%.

Compensation provided

Who can get screened?

People between the age of 2.5 and 45 with a parent, brother, sister, or child with type 1 diabetes.

People between the age of 2.5 and 20 with a grandparent, aunt/uncle, cousin, niece/nephew, or half-sibling with type 1 diabetes.

Contact Information

TrialNet

720-346-1034

HALI.BRONCUCIA@CUANSCHUTZ.EDU

Also available: *MRI imaging sub-study*

Morgan Sooy

303-724-5686,

MORGAN.SOODY@CUANSCHUTZ.EDU



#EPIConf2021

HALI.BRONCUCIA@CUANSCHUTZ.EDU



TRIALNET HYDROXYCHLOROQUINE PREVENTION STUDY

TrialNet is conducting the Hydroxychloroquine (HCQ) Prevention Study to determine whether the drug hydroxychloroquine (HCQ) can prevent or delay disease progression in participants age 3 or older who have two or more diabetes-related autoantibodies and normal glucose tolerance (stage 1). Capsule taken by mouth as instructed until progression to stage 2 T1D (abnormal glucose tolerance) or Stage 3 T1D (diabetes onset).

Compensation provided

Who is eligible?

Participants age 3 or older

Positive for two or more AAB and normal glucose tolerance (Stage 1).

Contact Information

Brenda Bradfield

Office 303-724-8595

BRENDA.BRADFIELD@CUANSCHUTZ.EDU



#EPIConf2021

[**BRENDA.BRADFIELD@CUANSCHUTZ.EDU**](mailto:BRENDA.BRADFIELD@CUANSCHUTZ.EDU)



TRIALNET TOLERANCE USING PLASMID IN PEOPLE WITH T1D STUDY (TN27, TOPPLE)

TrialNet is recruiting adults (age 18-45) diagnosed with type 1 diabetes in the past 48 months for a Phase I clinical study testing the safety of a new plasmid therapy (NNC0361-0041).

12-week treatment phase:

Weekly subcutaneous injections

First visit: 48-hour inpatient stay for observation

Other visits range from 4-7 hours

9-month follow up phase:

Four study visits for monitoring and testing

Compensation provided

Who is eligible?

Between the ages of 18 and 45

Diagnosis of T1D in the past 48 months

Willingness to comply with intensive diabetes management

Up to date on recommended immunizations

NOT be pregnant or planning to be pregnant

Contact Information

Morgan Sooy

303-724-5686

MORGAN.SOODY@CUANSCHUTZ.EDU



#EPIConf2021

MORGAN.SOODY@CUANSCHUTZ.EDU



PRV-003-001 (PROTECT)

A clinical research study for children and adolescents with newly-diagnosed type 1 diabetes

Participants will receive two 12-day courses of teplizumab infusions

2 out of 3 chance to receive drug vs placebo

Teplizumab has a 20-year research history and has been shown to delay the onset of T1D in at risk individuals by an average of 2 years

Participants will be compensated

Who can participate?

Newly diagnosed type 1 diabetics age 8-17

Within the first 2 weeks of diagnosis, because you will have to begin receiving drug within 6 weeks after you were diagnosed

Contact Information

Lexie Chesshir

303-724-1755

LEXIE.CHESSHIR@CUANSCHUTZ.EDU



#EPIConf2021

LEXIE.CHESSHIR@CUANSCHUTZ.EDU



MAS-1 ADJUVANTED ANTIGEN-SPECIFIC IMMUNOTHERAPEUTIC FOR PREVENTION AND TREATMENT OF TYPE 1 DIABETES (MER3101)

Involves receiving an Antigen-Specific Immunotherapeutic (ASI) vaccine or placebo to learn whether the vaccine targets certain immune cells causing disease (diabetes) while avoiding other cells of the immune system needed to maintain general health

Goal: prove that MAS-1 vaccine is safe and promotes anti-inflammatory pathways while decreasing auto-inflammatory actions in the body
2 injections of study drug or placebo into muscle
Compensation provided

Main Inclusion/Exclusion Criteria:

Be age 18-45 years old
Be diagnosed with Type 1 Diabetes within previous 2 years
Meet ADA criteria for Type 1 Diabetes; have 1 genetic marker for diabetes (islet autoantibody)
Have certain amount of C-peptide protein in blood (indicates some natural insulin production)
A1c under 9.5

Contact Information

Lexie Chesshir
303-724-1755

LEXIE.CHESSHIR@CUANSCHUTZ.EDU



#EPIConf2021

LEXIE.CHESSHIR@CUANSCHUTZ.EDU



TWIN FAMILY STUDY

Free screening for twins and their relatives for their risk of type 1 diabetes and celiac disease.

Goal: Learn more about the genetic and environmental factors that contribute to the early stages of and progression to type 1 diabetes

Close monitoring, education and early treatment are offered to eligible participants

Compensation provided

Who can participate?

Twins and their relatives

Contact Information

Morgan Sooy

303-724-5686

MORGAN.SOOY@CUANSCHUTZ.EDU



#EPIConf2021

MORGAN.SOOY@CUANSCHUTZ.EDU



IMMUNE BIOMARKERS

Scientists at the BDC are trying to understand why the immune system is targeting insulin-producing cells

Goal: Develop better therapies to treat & prevent T1D

Donate blood (3-4 tablespoons) to our research study

Compensation provided

We are recruiting:

T1D new onset (can donate during normal clinic blood draws)

1st degree relatives (1-45 years old)

Individuals without family history of autoimmune disorders

Contact Information

720-346-1034

HALI.BRONCUCIA@CUANSCHUTZ.EDU



#EPIConf2021

www.EPIConferences.org



ALL RESEARCH STUDIES AND CONTACTS

Bone Health In Adults With Type 1 Diabetes

Prakriti Joshee
303-724-9925
Prakriti.joshee@cuanschutz.edu

Autoimmunity Screening for Kids (ASK) study

303.724.1275
www.ASKhealth.org

Barbara Davis Center Colorado CGM Program

Katie Thivener
303-724-9998,
katelin.thivener@cuanschutz.edu

Use of the Guardian™ Connect System with Smart Connected Devices

Emily Fivekiller
Office 303-724-8916
Cell 720-446-8078
Email: Emily.Fivekiller@CUAnschutz.edu

Daily Predictors of Diabetes Self-Management in Adolescents/Young Adults with Diabetes

Emily Fivekiller
Office 303-724-8916
Cell 720-446-8078
Email: Emily.Fivekiller@CUAnschutz.edu

The Pediatric Artificial Pancreas (PEDAP) trial: A Randomized Controlled Comparison of the Control-IQ technology versus Standard Care in Young Children in Type 1 Diabetes

Cari Berget
720-454-6938
cari.berget@cuanschutz.edu

FOCUS

Drake Giese
Work: (303)-724-3878
Drake.Giese@cuanschutz.edu

PICLS (Pregnancy Intervention With a Closed Loop System)

Dr. Sarit Polsky, Principal Investigator:
Sarit.Polsky@cuanschutz.edu 303-724-8575 or
Lisa Sher, Research Coordinator:
Lisa.Sher@cuanschutz.edu 303-724-8369

TrialNet Pathway to Prevention (TN01)

TrialNet
720-346-1034,
HALI.BRONCUCIA@CUANSCHUTZ.EDU

MR Imaging sub-study

Morgan Sooy
303-724-5686
MORGAN.SOODY@CUANSCHUTZ.EDU

TrialNet Hydroxychloroquine Prevention Study

Brenda Bradfield
303-724-8595
BRENDA.BRADFIELD@CUANSCHUTZ.EDU

TrialNet Tolerance Using Plasmid in People with T1D Study (TN27, TOPPLE)

Morgan Sooy
303-724-5686
MORGAN.SOODY@CUANSCHUTZ.EDU

PRV-003-001 (PROTECT)

Lexie Chesshir
303-724-1755
LEXIE.CHESSHIR@CUANSCHUTZ.EDU

MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes (MER3101)

Lexie Chesshir
303-724-1755
LEXIE.CHESSHIR@CUANSCHUTZ.EDU

TWIN Family Study

Morgan Sooy
303-724-5686
MORGAN.SOODY@CUANSCHUTZ.EDU

Immune Biomarkers

Hali Broncucia
720-346-1034,
HALI.BRONCUCIA@CUANSCHUTZ.EDU



#EPIConf2021


www.EPIConfferences.org



FOLLOW CDF ON SOCIAL MEDIA!



Children's Diabetes Foundation



@CDFdiabetes



@CDFdiabetes

#EPIConf2021

www.EPIConf2021.org



HAVE QUESTIONS DURING A PRESENTATION?

List your comments or questions in the “Chat” feature at the bottom of the screen.

Your comments/questions will be addressed by the moderator at the end of each presentation.

**Need IT help or support?
Call Paul at (720) 219-0475**



#EPIConf2021

www.EPIConferences.org



THANK YOU TO OUR
SUPPORTING SPONSOR

dexcom

#EPICconf2021

www.Dexcom.com



WE WANT YOUR FEEDBACK!

On Sunday, May 23rd, all conference participants will receive an email with a link to a post-event survey.

You can win one of three, \$50 Amazon gift cards for your participation in the survey! Be sure to enter your email address at the bottom of the form for a chance to win!

Winners will be selected at random and will receive one \$50 Amazon gift card each.

#EPIConf2021

www.EPIConferences.org




WANT TO EDUCATE YOUR FAMILY AND FRIENDS? ORDER THE NEWEST 14TH EDITION PINK PANTHER BOOK TODAY!

Copies of the Pink Panther series can be purchased at the front desk of the Barbara Davis Center or by contacting the Children's Diabetes Foundation at 303-863-1200.

FOR ORDERS OVER 10 BOOKS:

Place your order by phone at (303) 863-1200 for discounted shipping or fill out the mail-in form and send with payment. International orders may require additional shipping charges. Forms can also be sent directly to Ben@ChildrensDiabetesFoundation.org along with payment information.



#EPIConf2021


ChildrensDiabetesFoundation.org/Books



WANT TO EDUCATE YOUR FAMILY AND FRIENDS? PRINT OFF YOUR OWN CDF EDUCATIONAL MATERIALS!

In an endeavor to inform the public about the signs and symptoms of type 1 diabetes, the Children's Diabetes Foundation has created materials that provide information about the signs and symptoms of type 1 diabetes.

We invite you to help raise awareness by printing your own to share with those you know!



#EPIConf2021


[ChildrensDiabetesFoundation.org/Printables](https://www.childrensdiabetesfoundation.org/Printables)



STAY IN THE KNOW! SIGN UP FOR CDF'S NEWSNOTES PUBLICATION

Every quarter, the Children's Diabetes Foundation publishes NewsNotes to keep subscribers informed about the Barbara Davis Center and the Children's Diabetes Foundation. This includes medical information and discoveries, cutting-edge research, social events, kids' games, and more!

See our past editions online at
www.issuu.com/cdfdiabetes



#EPIConf2021

ChildrensDiabetesFoundation.org/Newsnotes



CDF SUPPORT GROUPS

You are not alone with type 1 diabetes!

The Children's Diabetes Foundation holds diabetes support groups once a month in 10 Colorado locations,

1 Wyoming location, and 2 virtual groups. These groups are for anyone who is affected by type 1 diabetes – whether you have type 1 yourself or the friend, family, loved one, or caregiver of someone with type 1.

Scan the QR code to learn more and sign up for a Support Group!



#EPIConf2021

ChildrensDiabetesFoundation.org/Support-Groups



ADA IMAGINE CAMP

We know kids with type 1 diabetes (as well as the BDC staff!) love attending diabetes camp every summer! Due to the continued spread of COVID-19 and the increased risks of severe complications that people with diabetes face when they contract the virus, the ADA has decided to transition 2021 camps to virtual participation.

ADA Imagine Camp is offered through four one-week sessions, Monday through Friday, June 7–July 26 for youth ages 5–17. Daily sessions will include one-hour virtual meetups over Zoom. Youth will connect with peers through live activities guided by counselors and interact virtually with camp staff and other campers.

Families can register for one or multiple weeks **AT NO-COST!** You can start the registration process at www.Diabetes.org/ImagineCamp



Imagine Camp

#EPIConf2021

www.Diabetes.org/ImagineCamp



UPCOMING CDF FUNDRAISERS

Tory Burch Fundraising Event

Denver Premium Outlets

Online shopping event on June 24

In-store June 25-27

CDF's Tied to a Cure Denver Golf Tournament

Pinehurst Country Club

July 12

CDF's Annual Run for the Ring 5K and Fun Run

Barbara Davis Center, Anschutz Campus

August 7

Don't Sugar Coat it 5K

Redstone Park (Highlands Ranch)

August 15

Keep an eye on Children's Diabetes Foundation social media for more information on upcoming fundraisers!



#EPICconf2021

ChildrensDiabetesFoundation.org

